Akari provided an update at the American Society of Hematology (ASH) meeting on the Soliris-resistant patient who has now been well controlled with Coversin for nine months. New data were released supporting a once-daily dosing, with complete inhibition of hemolysis with 22.5mg and 30mg per day. The company also provided guidance on new indications either by leveraging Coversin’s leukotriene B4 activity, or its ease of derivatization into new longer lasting and targeted versions. Result
09 Jan 2017
ASH data highlight Coversin's unique properties
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
ASH data highlight Coversin's unique properties
- Published:
09 Jan 2017 -
Author:
Maxim Jacobs -
Pages:
8
Akari provided an update at the American Society of Hematology (ASH) meeting on the Soliris-resistant patient who has now been well controlled with Coversin for nine months. New data were released supporting a once-daily dosing, with complete inhibition of hemolysis with 22.5mg and 30mg per day. The company also provided guidance on new indications either by leveraging Coversin’s leukotriene B4 activity, or its ease of derivatization into new longer lasting and targeted versions. Result